bioAffinity Technologies, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.2M | $9.4M | $7.9M | $6.9M | — |
| Cost of revenue | — | — | — | $467 | — |
| Gross profit | — | — | — | $4,336 | — |
| Selling, general & administrative | $9.9M | $9.9M | $6.8M | $2.5M | $1.1M |
| Research and development | $1.4M | $1.5M | $1.5M | $1.4M | $1.0M |
| Operating expenses | $16.7M | $18.3M | $10.5M | $4.0M | $2.2M |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M | -$2.2M |
| Interest expense | $44,372 | $92,475 | $37,125 | $2.5M | $1.0M |
| Pretax income | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| Income tax expense | $44,042 | $11,650 | $20,993 | $2,459 | $1,950 |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| Balance Sheet | |||||
| Cash and equivalents | $6.4M | $1.1M | $2.8M | $11.4M | $1.4M |
| Current assets | $7.6M | $2.7M | $4.0M | $12.0M | $1.4M |
| Total assets | $11.0M | $6.5M | $8.2M | $12.2M | $1.5M |
| Current liabilities | $2.9M | $3.1M | $2.2M | $1.1M | $13.0M |
| Total liabilities | $3.7M | $3.9M | $3.4M | $1.1M | $13.2M |
| Stockholders' equity | $7.3M | $2.6M | $4.9M | $11.0M | -$15.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$9.3M | -$7.3M | -$6.0M | -$4.1M | -$2.0M |
| Depreciation and amortization | $170,359 | $162,332 | $233,064 | $10,182 | $4,817 |
| Stock-based compensation | $671,474 | $989,681 | $748,823 | $248,592 | $43,012 |
| Capital expenditure | $60,568 | $79,083 | $22,902 | $219,987 | — |
| Free cash flow | -$9.4M | -$7.3M | -$6.1M | -$4.3M | — |
Shares outstanding 4.5M · Free float 76.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.